Four Europeans are diagnosed with cancer every minute. Addressing this challenge requires sustained focus on therapeutic innovation. The European Medicines Agency has now published a Horizon Scanning Report specifically focused on radiopharmaceuticals. Excellent news for the industry and a significant recognition of therapeutic nuclear medicine’s role in cancer care.

As the voice of the European nuclear medicine industry, Nuclear Medicine Europe has maintained ongoing dialogue with EMA through our working groups, contributing to consultations and regulatory discussions on radiopharmaceuticals and therapeutic applications. EMA’s dedicated focus on this sector – which will propose recommendations to shape future regulatory frameworks – is recognition of the field’s importance and potential.

We look forward to continuing our role in ensuring industry expertise informs the development of frameworks that enable innovation while ensuring patient access to these life-saving therapies.

See EMA’s recommendations for the future of radiopharmaceuticals in Europe.

As part of Nuclear Medicine Europe’s commitment to develop closer working relationships with the European Association of Nuclear Medicine (EANM), we are pleased to announce our participation in the European Nuclear Medicine Forum to shape the future of Personalised Theranostics.

This 10-year initiative brings together experts in the field to develop a shared vision and strategic roadmap for the widespread integration of Personalised Theranostics into European healthcare systems by 2035.

The initiative is structured around five dedicated Task Forces. Nuclear Medicine Europe will co-lead two of these Task Forces, with Konrade von Bremen and Matt Morrison representing the association. Both will work alongside EANM clinical counterparts, ensuring the voice of the European nuclear medicine industry is clearly heard throughout the development process.

Further details will be shared at the General Assembly in June 2026.

Read more
EANM launches the European Nuclear Medicine Forum to shape the future of Personalised Theranostics

Nuclear Medicine Europe’s white paper examining the role of dosimetry in therapeutic radiopharmaceuticals (tRPs).

The paper addresses ongoing debate within the nuclear medicine community about whether individual dosimetry should be compulsory in clinical practice.

The paper calls for a coherent regulatory framework that recognizes the specificities of tRPs and emphasizes the need for multistakeholder dialogue to ensure guidelines remain both fit for purpose and future proof as this field continues to evolve.

Read the white paper

Our latest publication is an interview-based series entitled : “Beyond Imaging: Nuclear Medicine’s Next Decade”.

Drawing on the perspectives of Presidents of leading European nuclear medicine societies, this publication reflects on how the field has evolved over the past five years and how it may develop over the next decade. It examines recent technological and therapeutic advances, explores projections toward 2035, and identifies the clinical areas where nuclear medicine is expected to deliver the greatest impact.

Together, these contributions offer a structured and experience-based view of nuclear medicine at a time of rapid transformation, from the expansion of radioligand therapy and advanced imaging systems to the growing integration of data-driven and multidisciplinary approaches in clinical care.

Read the publication

Effective science communication is crucial in making complex topics accessible to diverse audiences. In this interview, we speak with Dr. Paulien Moyaert, a physician-scientist who has successfully leveraged digital media to demystify nuclear medicine. As the creator of a highly successful YouTube channel, she produces concise, engaging videos on a variety of medical topics, using 3D models, dynamic PowerPoint slides, and even real surgical footage.

From explaining intricate medical concepts to combating misconceptions, she shares her approach and experience in making scientific topics clearer and more engaging for professionals and the public alike.

Read the publication : Communicating nuclear medicine to a wider audience

“Nuclear Medicine Europe is a centralised association that brings together professionals, researchers and industry representatives to advance nuclear medicine across Europe. By fostering collaboration, sharing best practices, and advocating for regulatory and policy support, Nuclear Medicine Europe enhances the visibility and impact of nuclear medicine in healthcare. Through its initiatives, Nuclear Medicine Europe not only champions innovation but also strives to ensure that the benefits of nuclear medicine are accessible to all patients, reinforcing its essential role in modern medical practice.

Nuclear medicine is a vital and rapidly advancing field that plays a crucial role in the diagnosis, treatment, and management of various medical conditions, particularly cancer and cardiovascular diseases.”

“The renowned journal Nature recently published several review articles showing how nuclear medicine (NM) offers a new way of treating cancer. The aim of this article is to explain how and why this discipline, which dates back to 1940, has been reborn with a new revolution in medicine, thanks in particular to theragnostic, a particular method which uses the same biological vector for both imaging diagnosis and therapy, but with different radioelements as tracer.

The unique role of biology and nuclear physics The principle of nuclear medicine is based on the substitution of a stable isotope (e.g. Iodine 127) by its radioactive isotope (e.g. Iodine 131), called a tracer, within a chemically or biologically pathology-specific molecule (e.g. a protein or an antibody), called…”

What drives a doctor or a medical student to go into nuclear medicine? What has nuclear medicine brought you in terms of personal and professional satisfaction in your career? What would you say to medical students to encourage them to consider specialising in nuclear medicine? How do you see the future of nuclear medicine? (in medical terms, not in terms of recruitment issues)
The answers to these questions and more are available in the following article.

“In people’s mind, the discovery of an incommensurable amount of energy within the nucleus of atoms appeared to be double sided: on the upside, it was the hope of an infinite source of energy ensuring long-lasting well-being to humanity, and, on the downside, it was the fear that humanity may disappear if a huge amount of energy were inappropriately released. Nuclear medicine has emerged on the shiny side of the coin, raising the hope that ionising radiation released by nuclear energy would bring major benefits to human health: new methods to investigate all types of cellular mechanisms in vivo, and methods for the destruction of life-threatening cancer cells.”

“Nuclear medicine uses cutting-edge technology to diagnose and treat cancer effectively and efficiently. Advanced, accurate and safe, it is one of the most exciting, innovative areas of medicine, and is at the forefront of cancer treatment. How does it work, what can it achieve and how does it support Europe’s health objectives?”

A comprehensive introduction to nuclear medicine, which was made for the audience of the 2023 Nuclear Medicine Europe’s Symposium, was held at the European Parliament. 

Click on the images to download.

More resources about nuclear medicine are available at :
https://whatisnuclearmedicine.com/